Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of COS.

Clairity Breast Is Added to NCCN Guidelines for Breast Cancer Screening and Diagnosis

April 14, 2026

Ashling Wahner

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Less Is More: Advancing Care in TP53-Mutated Myeloid Malignancies

April 14, 2026

Mendel Goldfinger, MD

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

Emactuzumab Improves ORR, Functional Outcomes in Tenosynovial Giant Cell Tumor

April 14, 2026

Courtney Flaherty

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

Cema-Cel Improves MRD Clearance as First-Line Consolidation in Large B-Cell Lymphoma

April 14, 2026

Chris Ryan

The allogeneic CAR T-cell therapy cema-cel improved MRD negativity rates vs observation as first-line consolidation in LBCL.

First-Line Darovasertib Plus Crizotinib Yields PFS Benefit in Metastatic Uveal Melanoma

April 14, 2026

Ashling Wahner

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Sac-TMT Plus Pembrolizumab Demonstrates Durable Responses in Recurrent/Metastatic Cervical Cancer

April 13, 2026

Kyle Doherty

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer

April 13, 2026

Kristi Rosa

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Mirvetuximab Soravtansine Plus Carboplatin Is Active in Platinum-Sensitive Ovarian Cancer

April 13, 2026

Jason Broderick

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Later-Line Liso-Cel Yields Efficacy Benefits vs Real-World SOC for R/R Mantle Cell Lymphoma

April 13, 2026

Riley Kandel

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

Real-World Analysis Reiterates Importance of Performance Status, Toxicity Management With Mirvetuximab Soravtansine in Recurrent Ovarian Cancer

April 13, 2026

Courtney Flaherty

ECOG PS should be evaluated before initiating this agent, as patients with poorer PS may experience shorter life expectancy than reported in trials.

Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer

April 13, 2026

Ashling Wahner

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

FDA Grants Priority Review to BLA for Ifinatamab Deruxtecan in Pretreated ES-SCLC

April 13, 2026

Kyle Doherty

The FDA has accepted and granted priority review to the BLA seeking the approval of I-DXd in ES-SCLC.

CAR T-Cell Therapy: Could a Cancer Breakthrough Cure Autoimmune Diseases?

April 13, 2026

Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center researchers are investigating whether CAR T-cell therapy could target some of the most common autoimmune diseases.

Fixed-Duration Pirtobrutinib Plus Venetoclax/Rituximab Yields PFS Advantage in R/R CLL/SLL

April 13, 2026

Chris Ryan

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

Sofetabart Mipitecan Displays Antitumor Activity in Recurrent Platinum-Resistant HGSOC

April 13, 2026

Jason Broderick

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.